• Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries
  • Program supports Kenyan government on noncommunicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1
  • Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key …

Holzkirchen, October 14, 2015 – Last night in Madrid, Sandoz picked-up three accolades at the Global Generics & Biosimilars Awards hosted by the Generics Bulletin including Company of the Year.

The recent launch of Zarxio, the first US biosimilar, which has paved the way for greater access to high-quality biologics won Biosimilar Initiative of the Year. In September this year, Sandoz became the first company to introduce a biosimilar in the US – leading the way in the US just as it did in Europe nearly 10 years ago.

The …

  • Etanercept is an anti-TNF medicine used to treat a range of immunological diseases including rheumatoid arthritis and psoriasis.
  • Sandoz is seeking approval for all indications included in the reference product’s label.
  • Sandoz believes that the totality of evidence in its submission, including two pivotal clinical studies, will demonstrate that the proposed biosimilar is essentially the same as the reference product.

Holzkirchen, October 2, 2015 – Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US …

September 29, 2015 – An estimated 17.3 million people die of cardiovascular diseases every year. That makes it the number one cause of death in the world today, with 80% of those deaths occurring in low- and middle-income countries. Ischemic heart disease (e.g. heart attacks) is responsible for 7.3 million of total CVD deaths and cerebrovascular disease (e.g. strokes) for a further 6.2 million.

The big causes of cardiovascular disease

The …

  • First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
  • Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month
  • Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally1

New York, September 24, 2015 …

  • Sandoz is investing over 150 million euro and creating 100 new highly qualified jobs
  • The new BioInject facility will support Sandoz’s fast growing biosimilars business as well as other Novartis biologics
  • State-of-the-art technology will strengthen Sandoz and Novartis in-house capabilities in drug product manufacturing

Schaftenau, September 17 2015 – Sandoz, the generics and biosimilars business of Novartis, today officially opened its new cutting-edge biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria …

Holzkirchen, September 3, 2015 – Sandoz, a Novartis company, announced today that ZarxioTM (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the US.

“As the pioneer and global leader in biosimilars, Sandoz has maintained a commitment to bringing high-quality biosimilar medicines to patients and healthcare professionals around the world,” said Richard Francis, Global Head, Sandoz. “With the launch of Zarxio, we look forward to increasing …

Princeton, New Jersey, July 28, 2015– Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP.

Sandoz’s budesonide inhalation suspension product is indicated for maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Budesonide inhalation suspension is not indicated for the relief of acute bronchospasm.

“Asthma is unfortunately becoming increasingly prevalent while few …

  • Non-communicable diseases like asthma are rising rapidly in sub-Saharan Africa where healthcare systems are ill-prepared to cope1 – Zambia is ranked #1 in the world for mortality due to asthma2
  • Increasing the medical expertise of local healthcare professionals is a quick and sustainable way to improve patient health outcomes3,4
  • Sandoz is calling on European doctors with an interest in asthma to volunteer for Breathe Africa

Holzkirchen, July 24, 2015 – Sandoz today announced the launch of Breathe Africa, a respiratory …

Holzkirchen, Germany, July 22, 2015 – The US Court of Appeals for the Federal Circuit issued a ruling on July 21 that paves the way for Sandoz to launch Zarxio (filgrastim) after September 2, as the first US biosimilar.

The court, which ruled following an appeal hearing on June 3, found that provision of the biosimilar application to the originator company within 20 days of filing – the so-called “patent dance” component of the US biosimilar approval pathway, or BPCIA — is optional.

However, it also ruled that the required notice of commercial marketing can …